Alnylam Pharmaceuticals | ALNY - Interest Expense On Debt

Stock Price
332.79
Daily Change
3.44 1.04%
Monthly
-7.90%
Yearly
35.72%
Q1 Forecast
325.77

Alnylam Pharmaceuticals reported $129.34M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 22.5M 811K Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
Tectonic Therapeutic USD 277M 276.98M Sep/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.66M 578K Sep/2025